Last updated on September 2018

Dose Optimization Study of Idelalisib in Follicular Lymphoma


Brief description of study

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.

Clinical Study Identifier: NCT02536300

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

Centre Hospitalier Victor Dupouy d'Argenteuil
Argenteuil, France
1.76miles
  Connect »

Gilead Study Team

Hopital Saint Antoine
Paris Cedex 12, France
6.37miles
  Connect »

Gilead Study Team

Hopital Saint Louis
Paris Cedex 12, France
6.37miles
  Connect »